Media

Ariceum Therapeutics Granted UK Authorisation to Conduct Phase I Clinical Study of its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblastoma

Oncopeptides – Pepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica

Tom Plitz commences role as Chief Executive Officer of Precirix

Vicore publishes the year-end report

Vicore to Present at Upcoming Investor Conferences

Oncopeptides publishes year-end report 2023

Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial

Oncopeptides receives decision from the U.S. Food and Drug Administration confirming withdrawal of Pepaxto from the U.S. market

Oncopeptides receives positive recommendation for Pepaxti by Spanish Pricing Authority

Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer